Screener
Bristol-Myers Squibb BMY Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $12.97B+5.7% | $11.49B+2.6% | $12.5B+1.3% | $12.22B+2.8% | $12.27B+0.6% | ||
| $3.73B+10.5% | $3.42B+12.8% | $4.1B-14.9% | $3.44B+16.2% | $3.37B+3.2% | ||
| $9.25B+3.9% | $8.07B-1.2% | $8.41B+11.6% | $8.79B-1.7% | $8.9B-0.4% | ||
| 71.3%-1.2pp | 70.2%-2.7pp | 67.2%+6.2pp | 71.9%-3.2pp | 72.5%-0.7pp | ||
| $2.96B+14.7% | $2.65B+17.4% | $2.59B-19.0% | $2.53B+6.5% | $2.58B-11.0% | ||
| $1.83B+6.6% | $1.62B+2.1% | $2.18B+2.1% | $1.79B-9.8% | $1.71B-11.2% | ||
| $8.89B-15.3% | $8.25B+0.2% | $11.03B-9.3% | $9.11B-10.8% | $10.5B-3.8% | ||
| $61M+112% | —— | —— | $108M+146% | -$494M-81.0% | ||
| $4.09B+130% | $3.24B+9.1% | $1.47B— | $3.11B+85.8% | $1.77B+37.9% | ||
| $770M+67.4% | $561M+10.2% | $384M+288% | $919M+99.3% | $460M+216% | ||
| $3.32B+153% | $2.68B+9.0% | $1.09B— | $2.2B+81.8% | $1.31B-22.0% | ||
| 25.6%+14.9pp | 23.3%+1.4pp | 8.7%+8.7pp | 18%+7.8pp | 10.7%-3.1pp | ||
| $1.62+153% | $1.31+9.2% | $0.53— | $1.08+80.0% | $0.64-22.9% | ||
| $4.68B+68.1% | $3.83B-3.7% | $2.45B+30.2% | $4.13B-3.4% | $2.78B-28.3% | ||
| 36.1%+13.4pp | 33.4%-2.2pp | 19.6%+4.3pp | 33.8%-2.1pp | 22.7%-9.1pp | ||
| $4.09B+130% | $3.24B+9.1% | $1.47B— | $3.11B+85.8% | $1.77B+37.9% |
FAQ
- What is Bristol-Myers Squibb's revenue?
- Bristol-Myers Squibb (BMY) generated $49.2B in revenue over the trailing twelve months, up 3.1% year over year.
- Is Bristol-Myers Squibb profitable?
- Bristol-Myers Squibb reported $9.3B in net income over the trailing twelve months, a 18.9% net margin.
- What is Bristol-Myers Squibb's earnings per share?
- Bristol-Myers Squibb's diluted EPS over the trailing twelve months is $4.54.
- Where does Bristol-Myers Squibb's income statement data come from?
- Every line is extracted from Bristol-Myers Squibb's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
